Ipsen Sa · EURONEXT:IPN
Ipsen Sa — Q1 2024 Earnings Presentation
23 slides from Ipsen Sa's earnings presentation, Apr 24, 2024
Slide 1: Q1 2024 sales update
Q1 2024 sales update 24 April 2024 Janice Living with cervical dystonia, Tennessee, U.S.
Slide 2: Disclaimer and safe harbor
Disclaimer and safe harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements
Slide 3: Speakers
Speakers For Q&A David Loew Aymeric Le Chatelier CEO CFO 3
Slide 4: Today's highlights
Today’s highlights Strong top-line growth – Total sales +13.3% – Growth platforms1 +16.2% 2024 guidance3 – Increased contribution from new medicines2 confirmed Launches progressing Total-sales – Onivyde: encouraging early start in 1L mPDAC growth >+6% – Bylvay & Sohonos : launch on-going in the U.S.
Slide 5: Q1 2024 sales
Image O/S Q1 2024 sales €m % change Growth platforms1 509.7 16.2% New medicines2 45.5 n/a Somatuline® 257.8 -1.3% Other 9.5 -20.5% Total Sales 822.4 13.3% All growth rates at constant exchange rates. Packaging Operator 1 Dysport®, Decapeptyl®, Cabometyx® & Onivyde®. 2 Bylvay®, Tazverik® & Sohonos®.
Slide 6: Somatuline sales: -1.3%
Somatuline sales: -1.3% North Rest of Europe America World -10.0% +9.3% +14.7% Market-share gains in a Benefit from generic-competitor Ongoing strong performance growing NET market shortages in some markets & share gains in non-generic markets, including Latin America Continued adverse pricing from
Slide 7: Growth platforms: +16.2%
Growth platforms: +16.2% +19.3% +22.2% +2.6% +14.8%1 €177m €155m €131m €41m1 Strong performance Robust volume performance Strong growth Positive early start across aesthetics & supported by in China in 1L mPDAC therapeutics share gains in 1L Growing & attractive Favorable phasing in Increased compet
Slide 8: A good early start for Onivyde in 1L mPDAC
A good early start for Onivyde in 1L mPDAC Significant Potential potential, to become new standard of with high unmet care medical need U.S. FDA approval: 13 February Patients SoC Orphan Exclusivity in 1L to 2031 Positive uplift in post-launch ` demand “The approval of this Onivyde regimen is an imp
Slide 9: Dysport: strong growth across indications
Dysport: strong growth across indications Aesthetics +24.3% €102m – Strong performance in all markets in Ipsen & partner territories, including U.S. – Solid market growth ` – Phasing adversely impacted sales in Europe Therapeutics +12.9% €75m – Solid performance, driven by Rest of World & North Amer
Slide 10: New medicines: increased contributions
New medicines: increased contributions €26m €12m €7m Strong performance & patient uptake Solid demand growth Launch focus in U.S. on driving sense in PFIC, despite challenging pricing in a challenging of urgency to treat existing, mechanisms in Europe FL landscape diagnosed & identified patients Pro
Slide 11: Pipeline: near to mid-term outlook
Pipeline: near to mid-term outlook Key milestones Medicine 2024 2025 2026 Elafibranor 2L PBC, FDA, EMA Odevixibat ALGS, EMA Cabometyx mCRPC, Phase III (OS) Fidrisertib FOP, Phase IIb1 Bylvay BA, Phase III Dysport Migraine, Phase III Tazverik 2L FL, Phase III2 Data readout Regulatory decision 2L: sec
Slide 12: Conclusion
Conclusion On track to deliver 2024 roadmap Top-line momentum driven by growth platforms & launches of new medicines & indications Pipeline success & execution on external-innovation strategy Transformation & excellence in execution Mathilde Vincent, Scientist,R&D Senior Scientist, R&D, Les Ulis, Fr
Slide 13: Questions
QUESTIONS
Slide 14: Appendix
APPENDIX SIPSEN
Slide 15: Q1 2024 total sales: unfavorable impact of fx rates
Q1 2024 total sales: unfavorable impact of fx rates Q1 2024 sales by currency Average rate changes vs. € (Q1 2024 vs. Q1 2023) Other USD: 1.09 BRL: 5.37 AUD: 1.65 CNY: 7.80 TRY: 33.62 4% EUR -1% 33.3% -5% EUR -6% 26.7% 24.6% 34% 4% 33.5% -66% CNY 4% 3.3% 4.2% 35% USD BRL AUD CNY TRY 32.5% USD Unfavo
Slide 16: A balanced & sustainable pipeline
A balanced & sustainable pipeline Phase I Phase II Phase III Registration IPN60210 FIDRISERTIB CABOMETYX + ODEVIXIBAT1 R/R multiple myeloma ATEZOLIZUMAB FOP Alagille syndrome & R/R DLBCL 2L mCRPC IPN01194 ELAFIBRANOR TAZVERIK + R2 ELAFIBRANOR Solid tumors PSC 2L FL 2L PBC RITIVIXIBAT Oncology BYLVAY
Slide 17: Oncology
Oncology Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT(S) Second novel hormonal Cabometyx therapy (abiraterone & PFS endpoint met CONTACT-02 2L mCRPC 575 prednisone or enzalutamide) PFS, OS Phase III or Awaiting OS data NCT04446117 Cabometyx + atezoli
Slide 18: Oncology
Oncology Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT(S) IPN60210 R/R multiple Treatment-emergent adverse Phase I/Ib myeloma & 96 IPN60210 Recruiting1 events, dosing & ORR NCT05121103 R/R DLBCL IPN01194 Dose escalation, treatment Solid tumors Phase I
Slide 19: Rare Disease
Rare Disease Key ongoing clinical-trial highlights TRIAL POPULATION PATIENTS DESIGN PRIMARY ENDPOINT STATUS Elafibranor Response to treatment Placebo Regulatory decisions: ELATIVE defined as ALP < 1.67 x ULN 2L PBC 161 or U.S.: June 2024 Phase III and total bilirubin ≤ ULN and elafibranor E.U.: H2 2
Slide 20: Rare Disease
Rare Disease Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT(S) Odevixibat Placebo ASSERT Change from baseline in Regulatory decision: Alagille syndrome 52 or Phase III scratching score E.U.: H2 2024 odevixibat NCT04674761 10mg ritivixibat tablet QD for
Slide 21: Neuroscience
Neuroscience Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT IPN10200 Ax Moderate to Dose escalation & LANTIC severe upper facial 727 dose-finding versus Safety Active, not recruiting1 Phase II NCT04821089 lines Dysport or placebo IPN10200 Tx Adult pati
Slide 22: Investor Relations
Investor Relations Craig Marks Nicolas Bogler Vice President, Senior Manager, Investor Relations Investor Relations +44 7564 349 193 +33 6 52 19 98 92 craig.marks@ipsen.com nicolas.bogler@ipsen.com 22
Slide 23: Thank you
Thank you Follow us: www.ipsen.com